Beginning this year, american clinicians and researchers celebrated the news that the five-year survival rate for pancreatic cancer reached for the first time the two digits, up from just 6% in 2011. And while researchers at the University of Michigan Rogel Cancer Center and elsewhere continue to pursue scientific insights into the disease and develop new therapeutic approaches, surgeons on the front line of patient care are also working hard to improve outcomes. Hari Nathan, MD, PhD, an assistant professor of surgery at Michigan Medicine, sat down with the Michigan Health blog to talk about recent advances in surgical care for patients with pancreatic cancer, and some things patients should look for when evaluating where to seek treatment. Here’s part of the interview: “The best approach for treating pancreatic cancer remains physically removing the cancer through surgery, also called resection, in combination with chemotherapy and sometimes radiation therapy. It’s been known for decades that adding chemotherapy to resection for pancreas cancer improves survival. It’s a very difficult disease to begin with, and the survival rates are still unacceptably low compared to the progress scientists have made in a variety of other cancers. But rates are improving, and part of the reason they’re improving is the development of more effective chemotherapy regimens over time”.
Recently, surgeons at Michigan Medicine have adopted an emerging practice of administering some or all of a patient’s chemotherapy before they undergo an operation. One recent study, for example, found that patients who underwent chemo before surgery (known as neoadjuvant chemotherapy) had a two-year survival rate of 63.7% compared to 53.5% in those who received surgery first. According to Dr. Nathan that difference is driven by multiple reasons. Even in the best hands, these operations are challenging and can be fraught with complications. And clinicians know that when we give chemotherapy after an operation, roughly half of patients aren’t healthy enough to complete the intended course. Giving chemotherapy on the front end, before a major operation takes a toll on a patient’s body, increases the likelihood they’ll complete more of their chemotherapy, which, in turn, is correlated with better outcomes. For some patients, earlier administration of chemo could spare them from going through an operation if there are signs it won’t be effective. A small rate of patients will develop additional disease during chemotherapy, or have progression of the tumor. That’s a warning sign that their disease is more aggressive and putting them through a major operation may not be helpful to them”.
“In addition to improving the number of patients who complete their course of chemo, the neoadjuvant approach is also expanding the number of patients who are candidates for surgery. What we often find with these newer chemotherapy regimens is that they actually can kill parts of the tumor that will make an operation more viable. In the past, a patient may have been told that their tumor wasn’t resectable because it was wrapped around a vital artery. But if we can kill off the part of the tumor that was a barrier to a successful surgery, then it makes it possible to go in and do the operation. In a lot of ways, what we’re doing in pancreatic cancer now mimics what we’ve been doing in other cancers for a while,” he adds. “The difference is that in colorectal cancer, for example, we’ve had more effective chemotherapy agents, and so we’ve been willing to be more surgically aggressive. And now with pancreatic cancer, we’re finally getting to that point where we have these more effective chemotherapy regimens. There are a number of reasons why receiving care at a nationally ranked hospital or academic medical center, like Michigan Medicine, can also make a big difference for patients. The first is access to new, otherwise unavailable experimental treatments through clinical trials. Second, larger multidisciplinary centers will have more experience in specifically treating pancreatic cancer”
Indeed, Michigan Medicine was recently designated a National Pancreas Foundation Center of Excellence for Pancreatic Cancer, one of just two in the state. University of Michigan is a site for a trial enrolling patients who are not initially eligible for surgery because their pancreatic cancer involves major blood vessels or other tissue in the abdomen. The trial is to test an investigational medicine that helps chemotherapy to better attack the tumor, with a goal, ultimately, of making the patients candidates for surgery. Dr Nathan concludes proudly: “In addition to the quality of our surgeons, our medical oncologists, radiation oncologists, radiologists, geneticists and nutritionists all have expertise in pancreatic cancer. Everybody in our multidisciplinary pancreatic clinic has a large focus of their practice devoted to taking care of patients with pancreas cancer. That’s not the case everywhere”.
- Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.
Xiang M et al. Radiotherapy Oncol. 2020 Feb 7.
Assi HA et al. Oncologist. 2020 Feb; 25(2):e276.
Zaidi MY et al. J Surg Oncol. 2019; 119(1):5-11.
Lanfranca MP et al. J Surg Res. 2018; 232:570.
Dott. Gianfrancesco Cormaci
Ultimi post di Dott. Gianfrancesco Cormaci (vedi tutti)
- I farmaci ACE-inibitori: cosa sono, come funzionano e per cosa vengono utilizzati - Ottobre 6, 2022
- Anticoagulanti ed antiaggreganti piastrinici: una rassegna di base per sapere cosa sono e come si usano - Ottobre 6, 2022
- Retinoblastoma gets “viewed” from within: and the nuclear receptor hopes for drug solution sightin’ - Ottobre 6, 2022
- Vasculopatie e tumori che condividono meccanismi comuni: sulla comprensione di chi “spiana il terreno” per chi - Ottobre 6, 2022
- Ricerche sulla predisposizione all’embolia venosa nei tumori: le correlazioni con i gruppi sanguigni - Ottobre 6, 2022